Synchron raises $200M Series D to fund pivotal trial and next-generation interface

Synchron/Stentrode BCI

Synchron raised a $200 million Series D led by Double Point Ventures with ARCH, Khosla, Bezos Expeditions and new investors including Australia's National Reconstruction Fund and Qatar Investment Authority, bringing total funding to $345 million. The capital funds commercialisation of the Stentrode and development of a next-generation interface; 10 patients had been implanted to date.

• $200M Series D from Double Point Ventures, ARCH, Khosla, Bezos Expeditions and new investors.
• Total funding reaches $345M to commercialise Stentrode and develop next-generation endovascular BCI.
• Ten patients implanted at time of announcement; expansion planned across US, Canada and Australia trials.